BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

MultiStem regulatory update

FDA granted Orphan Drug designation for Athersys' MultiStem to prevent graft-versus-host disease (GvHD). MultiStem is in Phase I testing for the treatment of certain cancers...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >